Is a reduction in viability enough to determine biofilm susceptibility to a biocide?


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 3 3 2021
medline: 15 3 2022
entrez: 2 3 2021
Statut: ppublish

Résumé

The abundance and prevalence of dry-surface biofilms (DSBs) in hospitals constitute an emerging problem, yet studies rarely report the cleaning and disinfection efficacy against DSBs. Here, the combined impact of treatments on viability, transferability, and recovery of bacteria from DSBs has been investigated for the first time. Staphylococcus aureus DSBs were produced in alternating 48-hour wet-dry cycles for 12 days on AISI 430 stainless steel discs. The efficacy of 11 commercially available disinfectants, 4 detergents, and 2 contactless interventions were tested using a modified standardized product test. Reduction in viability, direct transferability, cross transmission (via glove intermediate), and DSB recovery after treatment were measured. Of 11 disinfectants, 9 were effective in killing and removing bacteria from S. aureus DSBs with >4 log10 reduction. Only 2 disinfectants, sodium dichloroisocyanurate 1,000 ppm and peracetic acid 3,500 ppm, were able to lower both direct and cross transmission of bacteria (<2 compression contacts positive for bacterial growth). Of 11 disinfectants, 8 could not prevent DSB recovery for >2 days. Treatments not involving mechanical action (vaporized hydrogen peroxide and cold atmospheric plasma) were ineffective, producing <1 log10 reduction in viability, DSB regrowth within 1 day, and 100% transferability of DSB after treatment. Reduction in bacterial viability alone does not determine product performance against biofilm and might give a false sense of security to consumers, manufacturers and regulators. The ability to prevent bacterial transfer and biofilm recovery after treatment requires a better understanding of the effectiveness of biocidal products.

Identifiants

pubmed: 33650476
pii: S0899823X21000428
doi: 10.1017/ice.2021.42
doi:

Substances chimiques

Disinfectants 0
Peracetic Acid I6KPI2E1HD

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1486-1492

Auteurs

Katarzyna Ledwoch (K)

School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom.
GAMA Healthcare, Watford, United Kingdom.

Maddalena Magoga (M)

School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom.

Dulcie Williams (D)

School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom.

Stefania Fabbri (S)

Perfectus Biomed Group, Cheshire, United Kingdom.

James Walsh (J)

Department of Electrical Engineering and Electronics, School of Electrical Engineering, Electronics & Computer Science, University of Liverpool, Liverpool, United Kingdom.

Jean-Yves Maillard (JY)

School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH